In pharmaceutical development, the final step - packaging - is often treated as a logistical formality. But for high-potency oral solid dose products, it's a critical function that directly impacts product integrity, regulatory compliance, and time-to-market. At Eirgen, we've made a strategic investment in bringing packaging in-house at our Westside Business Park site in Waterford. This decision has allowed us to maintain full control over the final stage of the product lifecycle, reducing complexity and accelerating delivery timelines for our partners.

Unlike many CDMOs that rely on external packaging vendors, Eirgen's integrated model eliminates the delays and risks associated with off-site transfers. Our packaging operations are fully embedded within our high-containment manufacturing environment, enabling seamless transition from production to finished supply chain - particularly important for high-potency compounds where containment and compliance requirements are stringent.

Packaging Room at Westside Business Park

Our primary packaging capabilities include the ACG High Speed BMAX Blister Machine, which supports both thermoform and cold-form blistering. It handles a wide range of dosage forms with consistent quality and high throughput, making it well-suited for commercial volumes. For products requiring unit-dose formats or individual containment, our Effytec Sachet Packer offers flexible packaging for powders and granules, operating under conditions appropriate for HPAPI handling. Both systems are designed to support rapid turnaround without compromising safety or regulatory standards.

ACG BMax Blister Machine

Secondary packaging is equally streamlined. Automated carton assembly, leaflet insertion, and tamper-evident sealing are supported by high-speed labeling systems that apply batch, expiry, and serialization data. We implement 2D Matrix Unit Serialization in full compliance with EU FMD and US DSCSA requirements, ensuring traceability and market readiness across global territories.

Eirgen's packaging facility operates under FDA, EMA, and HPRA standards, and supports both clinical and commercial supply. By integrating packaging with our high-potency CDMO offering, we provide partners with a reliable, compliant, and efficient solution that shortens timelines and strengthens supply chain control.

For sponsors developing high-potency therapies, Eirgen offers a clear operational advantage - faster market access through a fully contained, in-house packaging model.